Systemic therapy for primary hyperhidrosis: A retrospective study of 59 patients treated with glycopyrrolate or clonidine - 18/02/12
Reprint requests: Hobart W. Walling, MD, PhD, 1100 Sixth St, Suite 202, Coralville, IA 52246.Abstract |
Background |
Data regarding systemic medications in the management of hyperhidrosis (HH) are limited.
Objective |
The goal of this study was to provide evidence for the safety and efficacy of systemic medications for primary HH.
Methods |
A retrospective chart review was conducted of patients seen at an academic dermatology department prescribed systemic medications for primary HH.
Results |
A total of 71 patients were prescribed systemic agents. Twelve patients (17%) were lost to follow-up and were excluded from further analysis. A total of 59 patients with at least 2 months of follow-up data (mean age 28.9 ± 12.0 years; 37 women, 22 men; mean follow-up 19.5 months) were included in the analysis. Palmoplantar and/or axillary HH was most common (42/59; 71%); followed by generalized (9/59; 15%) and craniofacial (8/59; 14%) HH. Glycopyrrolate (generally 1-2 mg once or twice daily) was prescribed to 45 patients, with response rate of 67% (30/45). Fifteen treatment failures included 6 nonresponders and 9 with adverse effects, including xerostomia and gastrointestinal disturbance. Clonidine (0.1 mg twice daily) was prescribed to 13 patients, with a response rate of 46% (6/13). Seven treatment failures included 3 nonresponders and 4 with adverse effects, all relating to decreased blood pressure. One patient responded to oxybutynin at 5 mg twice daily. There were no significant differences in efficacy (P = .21; odds ratios 0.43, 95% confidence interval 0.12-1.5) or adverse effects (P = .46; odds ratios 1.78, 95% confidence interval 0.44-7.1) in comparing glycopyrrolate versus clonidine.
Limitations |
This was a retrospective study from a single, university-based population.
Conclusion |
Systemic therapy with glycopyrrolate or clonidine can be effective for HH. Nearly two-thirds responded to therapy, and less than a quarter had treatment-limiting adverse effects, all of which were self-limited and nonserious.
Le texte complet de cet article est disponible en PDF.Key words : anticholinergic, Catapres, craniofacial, hyperhidrosis, palmoplantar, Robinul, sweat
Abbreviations used : CI, HH, OR
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 66 - N° 3
P. 387-392 - mars 2012 Retour au numéro
Article précédent
- Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients
- Joy Wan, Katrina Abuabara, Andrea B. Troxel, Daniel B. Shin, Abby S. Van Voorhees, Bruce F. Bebo, Gerald G. Krueger, Kristina Callis Duffin, Joel M. Gelfand
- Clinicopathological consistency in skin disorders: A retrospective study of 3949 pathological reports
- Canan Aslan, Fatih Göktay, Ayşe Tülin Mansur, İkbal Esen Aydıngöz, Pembegül Güneş, Tuğba Rezan Ekmekçi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?